Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bio-Rad Laboratories ( (BIO) ) has shared an announcement.
Bio-Rad Laboratories provided an update on February 16, 2026, regarding its investment in Sartorius AG by disclosing selected 2025 financial metrics reported by Sartorius. For the year ended December 31, 2025, Sartorius posted €3.54 billion in sales revenue, €542.6 million in EBIT, and €230.4 million in net profit, alongside strong operating cash flow and a solid equity base, offering Bio-Rad stakeholders greater transparency into the financial health of a key strategic holding.
The disclosed Sartorius figures, prepared under IFRS and related standards, highlight a business with substantial non-current assets and a sizeable but balanced liability structure as of year-end 2025. By relaying these data while explicitly disclaiming responsibility for their accuracy, Bio-Rad reinforces its commitment to detailed reporting on significant equity investments without altering its own operational guidance, giving investors additional context for assessing the value and risk profile of its Sartorius stake.
The most recent analyst rating on (BIO) stock is a Hold with a $320.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.
Spark’s Take on BIO Stock
According to Spark, TipRanks’ AI Analyst, BIO is a Neutral.
The score is driven primarily by solid fundamentals—strong balance sheet and consistently positive free cash flow—tempered by volatile reported profitability and only modest revenue growth. Technicals are currently weak with the stock below key short/mid-term moving averages and negative momentum. The latest earnings call was mixed: conservative low-growth guidance and margin headwinds are offset by strong free cash flow outlook, ddPCR/Diagnostics momentum, and ongoing buybacks.
To see Spark’s full report on BIO stock, click here.
More about Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a life science research and clinical diagnostics company that develops and manufactures instruments, consumables, and reagents used in laboratories and healthcare settings worldwide. The company operates globally, serving pharmaceutical, biotechnology, academic, and clinical markets with technologies that support biological research and diagnostic testing.
Average Trading Volume: 225,646
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.14B
For detailed information about BIO stock, go to TipRanks’ Stock Analysis page.
